HIND
Vyome Holdings, Inc
Key Financials
Revenue
$319714
↑ 24.4%
Operating Income
$-10452570
↓ 35.3%
Net Income
$-10262007
↓ 43.9%
Gross Profit
$218771
↓ 95.7%
Total Assets
$6.5M
↑ 35.6%
EPS (Diluted)
$-4.86
↑ 64.9%
Total Liabilities
$2.7M
↓ 45.8%
Cash & Equivalents
$5.0M
↑ 619.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/29/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 4/29/2026 | View on SEC |
| DEF 14A | 3/31/2026 | View on SEC |
| PRE 14A | 3/20/2026 | View on SEC |
| 10-K | 3/18/2026 | View on SEC |
| 8-K | 2/25/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| 8-K | 1/28/2026 | View on SEC |
| 8-K | 12/23/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HIND |
| Company Name | Vyome Holdings, Inc |
| CIK | 1427570 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 949-429-6680 |